Hepatothermic therapy of obesity: rationale and an inventory of resources.
Hepatothermic therapy (HT) of obesity is rooted in the observation that the liver has substantial capacities for both fatty acid oxidation and for thermogenesis. When hepatic fatty acid oxidation is optimized, the newly available free energy may be able to drive hepatic thermogenesis, such that respiratory quotient declines while basal metabolic rate increases, a circumstance evidently favorable for fat loss. Effective implementation of HT may require activation of carnitine palmitoyl transferase-1 (rate-limiting for fatty acid beta-oxidation), an increase in mitochondrial oxaloacetate production (required for optimal Krebs cycle activity), and up-regulation of hepatic thermogenic pathways. The possible utility of various natural agents and drugs for achieving these objectives is discussed. Potential components of HT regimens include EPA-rich fish oil, sesamin, hydroxycitrate, pantethine, L-carnitine, pyruvate, aspartate, chromium, coenzyme Q10, green tea polyphenols, conjugated linoleic acids, DHEA derivatives, cilostazol, diazoxide, and fibrate drugs. Aerobic exercise training and very-low-fat, low-glycemic-index, high-protein or vegan food choices may help to establish the hormonal environment conducive to effective HT. High-dose biotin and/or metformin may help to prevent an excessive increase in hepatic glucose output. Since many of the agents contemplated as components of HT regimens are nutritional or food-derived compounds likely to be health protective, HT is envisioned as an on-going lifestyle rather than as a temporary 'quick fix'. Initial clinical efforts to evaluate the potential of HT are now in progress.
McCarty
M F
MF
Pantox Laboratories, San Diego, California 92109, USA.
D002334:Carnitine O-Palmitoyltransferase / Q000235:genetics; D005934:Glucagon / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D006979:Hyperthermia, Induced; D007328:Insulin / Q000378:metabolism; D008099:Liver / Q000378:metabolism* / Q000503:physiopathology; D009765:Obesity / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy*; D012333:RNA, Messenger / Q000235:genetics; D022722:Thermogenesis
D007328:Insulin; D012333:RNA, Messenger; D005934:Glucagon; D002334:Carnitine O-Palmitoyltransferase; D005947:Glucose